Artiva Biotherapeutics
Artiva is a biotech company specializing in NK cell-based therapies for autoimmune diseases and cancers. They are focused on developing innovative therapies like AlloNK® and CAR-NK candidates, with ongoing clinical trials for various autoimmune conditions. The company emphasizes a mission-driven culture dedicated to expanding treatment accessibility.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2019
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases. Their lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) across multiple clinical trials, including basket trials in rheumatoid arthritis and Sjögren's disease. The company leverages highly scaled, off-the-shelf, allogeneic NK cell manufacturing to make cell therapies broadly accessible to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Artiva Biotherapeutics.
9% below the average for this role
Postdoctoral Scholar
Case Western Reserve University
Senior Director, Quality Assurance GCP
Cogent Biosciences
Vice President, Clinical Operations
Alkeus Pharmaceuticals
IT-Expert / IT-Koordinator / IT-Administrator
IBIS Backwaren
IT Service Desk Manager
Lyell Immunopharma
UNIV - Staff Scientist I - Department of Pharmacology and Immunology
Medical University of South Carolina (MUSC)